Organization | Prostate Cancer Canada Network

Prostate Cancer Canada Network Report issue

Academic/Hospital Phase 2 Phase 3

Founded: Ottawa Canada (1993)

Organization Overview

First Clinical Trial

2010

NCT01653925

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Prostate Cancer Canada

Active Ingredients

Drugs in Phase 3 Trials (1)

sitagliptin (januvia) (1 trial)

Drugs in Phase 2 Trials (4)

darolutamide (Nubeqa) (1 trial)

degarelix acetate (firmagon) (1 trial)

docetaxel (taxotere) (1 trial)

lutetium (177Lu) vipivotide tetraxetan (Pluvicto) (1 trial)

Drugs in Other Trials (7)

acetylsalicylic acid (aspirin) (1 trial)

atorvastatin (lipitor) (1 trial)

dutasteride (avodart) (1 trial)

fluorocholine (1 trial)

pravastatin (pravachol) (1 trial)

rosuvastatin (crestor) (1 trial)

simvastatin (zocor) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Metabolic Syndrome (Phase 3)

Prostatic Neoplasms (Phase 3)

Syndrome (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 6
# of Trial APIs: 12